Drug Delivery Companies and Markets

Increase in chronic diseases, an increased demand for biologics, advancement of technology, and new product launches are some of the key factors which drive the evolution of the drug delivery technology market. Moreover, self-administration, residential care, increased demand for biosimilars, and generic medicine, supply vital growth opportunities for player operative within the market. On the other hand, risk of needle-stick injuries and side effects of medication might hinder the expansion of the market.

The global income for advanced drug delivery systems is expected to be $173.8 billion in the year 2019, demonstrating a compound annual growth rate (CAGR) of 2.8%.

Eminent personalities in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), Pfizer, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Bayer AG (Germany), 3M Company (U.S.), Merck & Co., Inc. (U.S.), Dickinson and Company (U.S.), Novartis AG (Switzerland), Becton, GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma.